AMGEN PRESENTS NEW DATA FOR FIRST-IN-CLASS IMDELLTRA™ (TARLATAMAB-DLLE) IN SMALL CELL LUNG CANCER AT WCLC 2024

Core Insights - Amgen presented new data on IMDELLTRA (tarlatamab-dlle), a bispecific T-cell engager targeting DLL3, at the 2024 World Conference on Lung Cancer, highlighting its potential in treating extensive-stage small cell lung cancer (ES-SCLC) [1][2][3] DeLLphi-303 Study Results - The Phase 1b DeLLphi-303 study showed that IMDELLTRA combined with PD-L1 inhibitors as first-line maintenance therapy in ES-SCLC had a manageable safety profile and positive survival outcomes [3][4] - IMDELLTRA plus durvalumab achieved a disease control rate (DCR) of 62.5% and a 9-month overall survival (OS) of 91.8% [3][4] - IMDELLTRA plus atezolizumab also demonstrated a DCR of 62.5% with a median duration of disease control of 7.2 months and a 9-month OS of 86.7% [3][4] DeLLphi-301 Study Results - Long-term follow-up data from the Phase 2 DeLLphi-301 study indicated an objective response rate (ORR) of 40% among 100 patients treated with IMDELLTRA [5][6] - The median OS for this group was reported at 15.2 months, with stable disease observed in 30% of patients [5][6] IMDELLTRA Overview - IMDELLTRA received accelerated approval from the FDA for patients with ES-SCLC who progressed after platinum-based chemotherapy [3][11] - The drug targets DLL3, which is expressed in approximately 85-96% of SCLC patients, making it a promising therapeutic target [10][11] Future Studies - Ongoing trials, including the Phase 3 DeLLphi-305 trial, will further evaluate the efficacy of IMDELLTRA in combination with PD-L1 inhibitors [3][4][6] - The DeLLphi-303 study is designed to assess the safety and efficacy of IMDELLTRA in combination with standard-of-care therapies in first-line ES-SCLC [6][8]